Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.
about
Molecular characterization of ambiguous mutations in HIV-1 polymerase gene: implications for monitoring HIV infection status and drug resistanceEvaluation of dried blood spots collected on filter papers from three manufacturers stored at ambient temperature for application in HIV-1 drug resistance monitoringHIV Drug Resistance in Antiretroviral Treatment-Naïve Individuals in the Largest Public Hospital in Nicaragua, 2011-2015HIV-1 drug resistance and resistance testing.HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapyLow levels of viral suppression among refugees and host nationals accessing antiretroviral therapy in a Kenyan refugee campField study of dried blood spot specimens for HIV-1 drug resistance genotypingPrevalence and virologic consequences of transmitted HIV-1 drug resistance in UgandaEarly immune adaptation in HIV-1 revealed by population-level approaches.Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, CanadaHIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patientsHIV drug resistance detected during low-level viraemia is associated with subsequent virologic failureDetection of cytomegalovirus drug resistance mutations by next-generation sequencing.Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy.Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men.HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5∆32/∆32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction.Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American EpidemicHIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, UgandaA method for killer-cell immunoglobulin-like receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma.Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by a near-full-genome population and deep sequencing approaches.Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.Determinants of virological failure and antiretroviral drug resistance in Mozambique.Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.Identification of major routes of HIV transmission throughout Mesoamerica.Comparison of Ahlstrom grade 226, Munktell TFN, and Whatman 903 filter papers for dried blood spot specimen collection and subsequent HIV-1 load and drug resistance genotyping analysis.Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir
P2860
Q28534497-BBC18773-204E-488F-85C9-F2F0B32EA611Q28543688-65DD43F8-DC00-401D-9231-9109437BBBA4Q28554725-CC5928C5-6245-4072-905B-71FE3C181EF8Q30245693-93C06C0F-916F-4FE5-B129-177ADE37D692Q33669836-1BAA4171-F5B6-4951-9B2B-F2B9BEEDD058Q33721466-9FA1AE10-6B79-4D4C-9990-918D4E00797FQ33742478-B16F730A-30BA-4DB1-82AD-337FCF9B7F29Q34058841-A4533B36-E43D-4CE1-83EC-C33008F02B31Q34116836-EAB913AC-281E-4989-BBBC-1C9C58C4BCB5Q34308788-CAAA438E-CD09-4A17-A4D0-D64C10CC3035Q34415820-4E6F353A-7BA0-4E5D-B643-A8E8A8E29DAEQ34508492-734988AD-AC9F-4E34-BB25-93E59B18F3F9Q34781706-780D8279-13D2-4EB6-9B06-E23F6C751F40Q34975934-40A44326-521D-4C0E-93FD-620CAECBE359Q35156765-E27B1225-1100-4C47-B6D6-15E845A69055Q36032235-54DB41F0-92EB-4A71-98FB-1384EA50BC85Q36120059-B33E2E0B-1A28-4A7B-B5AE-91BC69FA47F6Q36158371-EC2F20AA-0F76-47F9-A734-75D705E56001Q36274049-7BC2EBF2-1BDA-4BA2-A221-5AB28F702C32Q36343848-EBFF9931-EF75-4185-A96F-603FD50D4DCBQ36414604-7A3A490D-3DF3-4E47-B931-7CA46467BBCAQ36418462-E7FA25FF-6BEF-43A2-B4A0-B9DCCCA317E4Q36481449-C48AEE96-E700-4A4E-8E45-192074BB98E0Q36506119-B6A64C19-12E9-46B2-B630-D5066A66F826Q36922133-240DDA6F-407A-4D0A-989A-3EDA3293D52FQ37005868-0416F758-19CF-4C0F-A6AE-AB8802DD7C1EQ37048027-15A9AA46-E9B4-419C-A603-A0510D2C1F90Q37094767-9D1C7EEC-AEA1-498C-AFCB-8F8919E39B99Q37547823-B9A06433-EB2B-475F-9816-07032064BB44Q38612752-F2E4CE20-B4E2-43E7-BD33-186275060385Q38738833-98117C7C-64EE-4A66-83DD-08A3290962A5Q38963716-7DAA9815-59D4-4610-BFAD-0C73F9CF954DQ39149710-DC4EAB8E-AF51-4835-8215-520281AB1D75Q39414398-C5C05CA9-656B-41FD-89B8-444617B4F9F4Q39536633-80E43F04-FCD5-43EE-B8C4-D1F11B98FC91Q39835202-ED97EEA4-6098-4EF2-B813-8C772AA94310Q40118634-AE3A247A-C3E4-4377-95EA-873002AE7114Q40147603-F00EE55F-C0BA-445D-89A4-DEAD67715FD4Q40796505-89F259D5-FF4B-4185-BBC0-35BAAA2F8D43Q41127462-D71863CE-E024-4B28-A47A-2FE3AE5BF1BE
P2860
Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Automating HIV drug resistance ...... ssible sequence analysis tool.
@en
Automating HIV drug resistance ...... ssible sequence analysis tool.
@nl
type
label
Automating HIV drug resistance ...... ssible sequence analysis tool.
@en
Automating HIV drug resistance ...... ssible sequence analysis tool.
@nl
prefLabel
Automating HIV drug resistance ...... ssible sequence analysis tool.
@en
Automating HIV drug resistance ...... ssible sequence analysis tool.
@nl
P2093
P2860
P356
P1476
Automating HIV drug resistance ...... ssible sequence analysis tool.
@en
P2093
Anna L Chu
Brian Wynhoven
Celia K S Chui
Christina Trevino
Conan K Woods
P Richard Harrigan
Robert W Shafer
Tom A Hall
Tommy F Liu
P2860
P304
P356
10.1128/JCM.06689-11
P407
P577
2012-03-07T00:00:00Z